Group | Variable | Multivariable model 4 | |
---|---|---|---|
Odds ratio (95% CI) | P value | ||
Entire sample (n = 8157) | Increase in Cl−, mmol L− 1* | ||
Q1: ≤1 mmol L− 1 | 1 | (0.802) | |
Q2: 1–3 mmol L− 1 | 1.22 (0.65, 2.28) | 0.542 | |
Q3: 3–6 mmol L− 1 | 0.86 (0.46, 1.62) | 0.642 | |
Q4: > 6 mmol L− 1 | 1.00 (0.53, 1.89) | 0.992 | |
Interaction of Cl− increase with eGFRa | |||
Increase in Cl−: Q1 * eGFR: ≥ 90 | 1 | (0.960) | |
Increase in Cl−: Q2 * eGFR: 60–89 | 0.62 (0.23, 1.67) | 0.348 | |
Increase in Cl−: Q2 * eGFR: 30–60 | 1.01 (0.31, 3.30) | 0.990 | |
Increase in Cl−: Q2 * eGFR: < 30 | 0.00 (0.00) | 0.996 | |
Increase in Cl−: Q3 * eGFR: 60–89 | 1.14 (0.46, 2.79) | 0.780 | |
Increase in Cl−: Q3 * eGFR: 30–60 | 1.44 (0.48, 4.37) | 0.518 | |
Increase in Cl−: Q3 * eGFR: < 30 | 2.52 (0.38, 16.95) | 0.342 | |
Increase in Cl−: Q4 * eGFR: 60–89 | 0.96 (0.38, 2.44) | 0.937 | |
Increase in Cl−: Q4 * eGFR: 30–60 | 1.52 (0.50, 4.62) | 0.460 | |
Increase in Cl−: Q4 * eGFR: < 30 | 2.53 (0.38, 17.01) | 0.341 |